Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30340748 | 1.00 | KMT2A (0.59) | KMT2AFABP5PTPN1CD274EPHX2 | |
| SCHEMBL348791 | 1.00 | KMT2A (0.59) | KMT2AFABP5PTPN1CD274EPHX2 | |
| SCHEMBL14438907 | 0.93 | KMT2A (0.48) | KMT2AFABP5PTPN1CD274EPHX2 | |
| SCHEMBL1290289 | 0.91 | KMT2A (0.62) | KMT2AFABP5CD274EPHX2CASP3 | |
| SCHEMBL11888362 | 0.91 | KMT2A (0.47) | KMT2AFABP5PTPN1CD274EPHX2 | |
| SCHEMBL14891353 | 0.88 | KMT2A (0.43) | KMT2AFABP5PTPN1CD274EPHX2 | |
| SCHEMBL118248 | 0.88 | KMT2A (0.62) | KMT2AFABP5PTPN1EPHX2CASP3 | |
| SCHEMBL15521041 | 0.87 | KMT2A (0.45) | KMT2AFABP5PTPN1CD274EPHX2 | |
| SCHEMBL3127362 | 0.87 | KMT2A (0.55) | KMT2AFABP5PTPN1EPHX2CASP3 | |
| SCHEMBL12638185 | 0.84 | KMT2A (0.44) | KMT2AFABP5PTPN1CD274EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4311832-A1 | PHOTOCAGED OREXIN-B | Universität Zürich (CH) | 2024-01-31 | — | — | EP | claimed |
| CN-114230633-B | Polypeptide capable of repairing oxidative stress injury and preparation method and application thereof | 浙江湃肽生物股份有限公司 | 2023-05-30 | — | — | CN | claimed |
| US-12612619-B2 | Compositions and methods for improved gene editing | UNIVERSITY OF MASSACHUSETTS (US) | 2026-04-28 | — | — | US | disclosed |
| US-12565506-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | Clarity Pharmaceuticals Ltd (AU) | 2026-03-03 | — | — | US | disclosed |
| EP-3727435-B1 | BIVALENT NUCLEIC ACID LIGANDS AND USES THEREFOR | UNIV CARNEGIE MELLON (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4683911-A1 | NOVEL TAG FOR LIQUID-PHASE PEPTIDE SYNTHESIS | CordenPharma International GmbH (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-20250369027-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | TWIST BIOSCIENCE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4640701-A2 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4638480-A1 | AMYLIN RECEPTOR AGONISTS | Novo Nordisk A/S (DK) | 2025-10-29 | — | — | EP | disclosed |
| US-20250313604-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2025-10-09 | — | — | US | disclosed |
| CN-108712913-B | Tri-part modulators of endosomal G protein-coupled receptors | 武田药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| US-11332495-B2 | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix | RK Pharma Solutions LLC (US) | 2022-05-17 | — | — | US | disclosed |
| WO-2022096736-A1 | COMPOUNDS AND THEIR USE IN TREATMENT OF TACHYKININ RECEPTOR MEDIATED DISORDERS | EMBARK BIOTECH APS (DK) | 2022-05-12 | — | — | WO | disclosed |
| EP-3993820-A1 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 | Cadila Healthcare Limited (IN) | 2022-05-11 | — | — | EP | disclosed |
| US-11324832-B2 | Tripartite modulators of endosomal G protein-coupled receptors | ENDOSOME THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325945-B2 | Peptide based PCSK9 vaccine | CADILA HEALTHCARE LIMITED (IN) | 2022-05-10 | — | — | US | disclosed |
| US-11319343-B2 | Method of treatment | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2022-05-03 | — | — | US | disclosed |
| EP-3987024-A1 | COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING | University Of Massachusetts (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3988123-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | Janssen Pharmaceutica NV (BE) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565506-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | CA12, CLTC, CA13 | KMT2A 2695/4885FABP5 3555/4885PTPN1 2231/4885 |
| US-11325945-B2 | Peptide based PCSK9 vaccine | PCSK9, PCSK7, PCSK6 | KMT2A 2907/4885FABP5 516/4885PTPN1 1577/4885 |
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, INSR | KMT2A 2881/4885FABP5 94/4885PTPN1 1989/4885 |
| US-11324832-B2 | Tripartite modulators of endosomal G protein-coupled receptors | NTSR1, NTSR2, MRGPRX2 | KMT2A 2755/4885FABP5 2424/4885PTPN1 2372/4885 |
| US-11332495-B2 | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix | PEPD, DNPEP, PREP | KMT2A 2862/4885FABP5 4499/4885PTPN1 4741/4885 |
| US-12612619-B2 | Compositions and methods for improved gene editing | ALKBH2, ALKBH1, ALKBH3 | KMT2A 582/4885FABP5 2689/4885PTPN1 3749/4885 |
| US-20250313604-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | KMT2A 4134/4885FABP5 105/4885PTPN1 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.